Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholecalciferol (Vitamin D3) is a secosteroid produced naturally in human skin upon exposure to ultraviolet B radiation or obtained from dietary sources. It is biologically inactive until it undergoes two sequential hydroxylations—first by CYP2R1 or CYP27A1 enzymes in the liver forming calcifediol [25(OH)D], then by CYP27B1 enzyme primarily in the kidney forming calcitriol [1,25(OH)₂D₃], which is hormonally active. Calcitriol binds to and activates the nuclear vitamin D receptor (VDR), modulating gene expression related to calcium absorption and bone health. Deficiency leads to rickets or osteomalcemia; excess can cause hypercalcemia[2][4][7].
Cholecalciferol is biologically inactive and must be converted in the body to its active forms. It undergoes two hydroxylation steps—first in the liver to 25-hydroxycholecalciferol (calcifediol), then in the kidney to 1,25-dihydroxycholecalciferol (calcitriol). Calcitriol acts as a ligand for the vitamin D receptor (VDR), which regulates gene transcription involved in calcium and phosphate metabolism[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholecalciferol.